References: 1. Wienke S, Gordon S, Liang S, et al. Quantification of tumor fraction and outcomes association in a real-world non-small cell lung cancer (NSCLC) cohort using a tissue agnostic epigenomic circulating tumor DNA (ctDNA) assay. Cancer Res. 2024;84(6_suppl):Abs 2490. Accessed March 19, 2024. https://doi.org/10.1158/1538-7445.AM2024-2490
2. Rosen E, Schonhoft JD, Silverman IM, et al. Circulating tumor DNA (ctDNA) genomic and epigenomic profiling (Guardant Infinity) for diagnosis of DNA damage repair (DDR) loss-of-function (LoF) and response monitoring in the TRESR and ATTACC trials. Mol Cancer Ther. 2023;22(12_suppl):A123. Accessed March 19, 2025. https://doi.org/10.1158/1535-7163.TARG-23-A123
3. Guardant Health data on file. Guardant Health, Inc. Redwood City, CA.
4. Nakamura Y, Tsukada Y, Matsuhashi N, et al. Multiomic analysis for minimal residual disease detection: addressing challenges in stage Il-Ill colon cancer from COSMOS CRC-01. J Clin Oncol. 2024;42(3_suppl):Abs 180. Accessed March 19, 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.3_suppl.180
5. Elliott M, Fuentes-Antrás J, Dou A, et al. Longitudinal evaluation of circulating tumour DNA in early breast cancer using a plasma-only methylation-based assay. Ann Oncol. 2023;34(suppl 2):S278-S324. Poster 310P. Accessed April 2, 2024. https://www.annalsofoncology.org/article/S0923-7534(23)01342-X/fulltext
6. Janni W, Huober J, Braun T, et al. Multiomic, plasma-only circulating tumor DNA (ctDNA) assay identifies breast cancer patients with minimal residual disease (MRD) and predicts distant recurrence. Poster presented at: American Association for Cancer Research Annual Meeting; April 8-13, 2022; Philadelphia, PA. Accessed March 19, 2025. https://doi.org/10.1158/1538-7445.AM2022-3403
7. Elliot MJ, Fuentes-Antrás J, Main S, et al. Tumor-agnostic ctDNA monitoring in patients with metastatic HR+/HER2- breast cancer receiving CDK4/6 inhibitors and endocrine therapy. Presented at: AACR Annual Meeting; April 5-10, 2024; San Diego, CA. Abs 2490.
8. Podany EL, Foffano L, Gerrantana L, et al. Racial differences in genomic profiles and targeted treatment use in ER+ HER2- metastatic breast cancer. J Clin Oncol. 2024;42(16_suppl):Abs 1017. Accessed March 18, 2025. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.1017
Multiple studies demonstrate Guardant Infinity’s
high specificity and sensitivity for methylation-based
MRD detection
without requiring up-front tissue1-8
QUANTIFY CANCER
New studies support
methylation-based
ctDNA detection with Guardant Infinity after curative intent therapy.1-8
ctDNA, circulating tumor DNA; MRD, minimal residual disease.
Home Guardant Infinity™ for BioPharma Guardant360® CDx for BioPharma GuardantINFORM for BioPharma